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The purpose of this paper was to determine the cardiac status in children 15 years or more after adriamycin therapy for a solid
tumour. Of the 447 pts, 229 pts were fully studied and 218 were not. The following cardiac evaluations were proposed to all the 447
consecutive patients (pts): (1) cardiac Doppler US by one of two expert cardiologists; (2) cardiac rhythm and conduction
abnormalities including 24-hour holter ECG; (3)
131l-mlBG myocardial scintigraphy; (4) serum brain natriuretic peptide levels at rest;
(5) an exercise test with VO2 max measurement. The radiation doses delivered to 6 points in the heart were estimated for all
patients who had received radiotherapy. Congestive heart failure was diagnosed in 24 of 229 (10%) evaluated pts, with a median
interval of 15 years (0.3–24 years) from the first symptom after adriamycin treatment. Among the 205 remaining pts, 13
asymptomatic pts (6%) had severe (n¼4) (FSo20%) or marked (n¼9) (20pFSo25%) systolic dysfunction. In the 192 others, the
median meridional end-systolic wall stress was 91 (53–135) and it exceeded 100gcm
 2 in 52 pts. Using a Cox model, only the
cumulative dose of adriamycin and the average radiation dose to the heart, were identified as risk factors for a pathological cardiac
status. In conclusion, the risk of cardiac failure or severe abnormalities increases with adriamycin treatment, radiotherapy and time
since treatment, even after a follow-up of 15 years or more. In our series, after an average follow-up of 18 years, 39% of the children
had a severe cardiac dysfunction or major ventricular overload conditions. The risk increases with the dose of adriamycin and
radiation received to the heart, without evidence for threshold.
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Despite strong evidence for the cardiac toxicity (Von Hoff et al,
1979; Grenier and Lipshultz, 1998) of anthracyclines, they continue
to be among the most frequently used cytotoxic agents in adult and
paediatric oncology more than 30 years after their discovery
(Abraham et al, 1996; Hortobagyi, 1997). The late cardiac events
among long-term childhood leukaemia and cancer survivors were
first described in 1991 (Lipshultz et al, 1991; Steinherz et al, 1991,
1993), then later confirmed by many other teams. It was
hypothesised that the loss of myocytes during anthracycline
therapy might impair myocardial growth and lead to a gradual
increase in left ventricular afterload and sometimes reduced
contractility (Lipshultz et al, 1991, 1995; Grenier and Lipshultz,
1998). An increased risk was found to be associated with
mediastinal radiotherapy and the time since drug administration
(Steinherz et al, 1991, 1993): the role of pregnancy, delivery, and
weight-lifting activities in revealing cardiac deficits (Steinherz et al,
1993, 1995) was highlighted. The frequency of cardiac abnormal-
ities according to the anthracycline dose has been correlated with
age at treatment, the time elapsed since treatment, and sex
(Lipshultz et al, 1995; Silber et al, 1993; Steinherz et al, 1995). More
recently, a review listed all the studies in order to identify well-
known risk factors for cardiac abnormalities (Kremer et al, 2002).
However, to date, no study with such a large series of patients
and a minimum follow-up of 15 years, has attempted to undertake
a comprehensive evaluation of cardiac parameters with techniques
other than Doppler US, and controlled for drugs other than
adriamycin and for the radiation dose received by the heart at the
time of radiotherapy, whatever the target organ.
METHODS
Patients
A total of 447 consecutive patients (pts) who received at least one
dose of doxorubicin or daunorubicin (only two pts) between 1968
and 1982 and who were alive at the end of treatment of a solid
tumour at the Institut Gustave Roussy (IGR) were selected. Clinical
and histopathological characteristics of the cancers, the type of
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ltreatment, detailed information on chemotherapy, follow-up data,
and medical information about second cancers, were extracted
from hospital clinical records.
Information about the vital status and the date and cause of
death of each patient was obtained from the National Institute of
Statistics and Economic Studies (INSEE). For each dead patient,
the initial, immediate, and associated causes of death, coded
according to the 9th version of the International Classification of
Diseases, were obtained from the Center of Epidemiology on
Medical Causes of Death at the National Institute of Health and
Medical Research (Ce ´piDc INSERM) for every patient who had
died during the 1969–1999 period.
Cardiac evaluation
A letter was sent to each living patient in order to propose to him
the following investigations by an expert team of cardiologists:
1. Cardiac Doppler Ultrasonography by one of two expert
cardiologists: measurements of the left ventricular (LV) and
derived variables were made from both M-mode and two-
dimensional echocardiograms. M-mode measurements were made
at the tip of the mitral valve or just below. LV internal dimensions
and septal and posterior wall thickness were measured at end
diastole and at end systole over an average of up to five cardiac
cycles, according to the American Society of Echocardiography
recommendations (Schiller et al, 1989). Blood pressure was
measured with subjects lying supine for at least 15min in a quiet
room before the echocardiogram, using a mercury sphygmoman-
ometer. The three main derived variables used to define cardiac
abnormalities were calculated as follows:
  Fractional shortening (FS) (%)¼(LVEdD LVEsD)/LVEdD
where LVEdD is the left ventricular end-diastolic diameter, and
LVEsD, the left ventricular end-systolic diameter. Normal FS
value X28% in healthy adults.
  Ejection fraction (EF) (%)¼ (LVEdV LVEsV)/LVEdV
where LVEdV is the left ventricular end-diastolic volume, and
LVEsV the left ventricular end-systolic volume; the left
ventricular volumes were calculated according to the Teichholz
equation: V¼ (7/2.4þD) D
3. Normal EF value X60% in
healthy adults.
  End-systolic meridional wall stress (ESWS) was calculated using
the Sandler–Dodge formula (Sandler and Dodge, 1963) for a
thin-walled prolate ellipsoid:
Stress (in kdynescm
 2)¼(1.333 SBP 2r)/h(2rþh) where
1.333 is the conversion factor from mmHg to kdynes, SBP is the
cuff systolic blood pressure, and r (radius; 2r¼LVEsD) and h
(thickness) correspond to (systolic septal wall thicknessþsystolic
posterior wall thickness)/2.
One kilodyne (kdyne), i.e. 10
3 dynes E 1.01972gforcecm
 2, i.e.
E1gcm
 2
ESWS normal values¼68718kdynescm
 2 as measured in 50
normal subjects (Ganau et al, 1990).
2. A 24-hour holter ECG registered on a portable audiotape.
3.
123l-mlBG myocardial scintigraphy, calculating the cardiac to
mediastinum fixation ratio at the fourth hour (CM4) after an
isotope injection. This ratio is a good indicator of the catechola-
mine uptake by the myocardiac muscle cells. In case of decrease in
such a ratio, it can be concluded that the sympathetic myocardium
innervation has been decreased, according to the number of
muscle cells killed.
4. Serum brain natriuretic peptide (BNP) levels at rest.
5. Exercise test with VO2 maximum consumption (VO2 max)
measurement.
6. Left ventricular diastolic function, measured by the E wave/A
wave ratio, which is the ratio between the ‘peak Early diastolic
phase filling’ and the ‘Atrial diastolic phase filling’. It measures the
left ventricular diastolic dysfunction, characterised by a decrease
of the early diastolic filling and an increase of the atrial diastolic
filling. Ratios lower than 1.5 are considered as suspicious and
ratios lower than 1 as clearly abnormal (Bu’Lock et al, 1995).
The presence of a cardiac abnormality was defined as one of the
following criteria: either one cardiac failure episode with clinical
congestive signs, according to NYHA classification, or, in
nonsymptomatic patients, alteration of any of these three
parameters: FSo25% and/or EFo50% and/or ESWS490gcm
 2.
Dosimetry
Radiotherapy data were obtained from technical radiotherapy
records by hospital physicists. Among the 447 pts, 245 had
received radiotherapy at some site in the body. Whatever the site
of the target volume, the mean radiation dose to the heart for each
patient who had received external radiotherapy, we used a
computer program called ‘Dos_EG’ to calculate these data (Diallo
et al, 1996; Shamsaldin et al, 1998). Six anatomical points for dose
estimations were taken into account in the heart, and the mean
dose of radiation received to the heart was estimated, for each
patient, as the mean dose to these six anatomical sites.
Among the 245 pts who had received external radiotherapy, the
mean dose to the heart was 6.7Gy, but the median dose was only
3.7Gy (range: 0.001–91). Despite the variations in treatment
machines, the mean dose to the heart did not vary according to the
calendar period: 6.7Gy before 1975, 6.7Gy between 1976 and 1980,
and 6.9Gy after 1981.
Statistical analysis
The cumulative incidence of cardiac failure was determined using
the Kaplan–Meier method, and risk factors for cardiac failure were
identified using Cox’s proportional hazard regression models
(Breslow and Day, 1987). Assessment of relationships between
cardiac parameters was conducted using linear regression, after
transformation when they were abnormal. As the cardiac status
was assessed at a time that we decided (i.e. at the time of the
cardiac investigation), it was not possible to ascertain the time of
onset of an abnormal cardiac status; therefore, we were unable to
study the temporal pattern of the occurrence of this event. Risk
factors for a pathological cardiac status were identified via logistic
regression models (Breslow and Day, 1980).
RESULTS
Of the 447 pts, 218 pts did not participate in the study because they
refused to participate (n¼174), were lost to follow-up (n¼37), or
were dead (n¼7). The causes of death were as follows:
Creutzfeldt–Jakob disease (n¼2), second malignancy (n¼2),
suicide, car crash, and unknown cause (n¼1).
Of the 229 other pts, 205 were examined according to the
previously described protocol, and 24 were not examined but were
included in the study because they had experienced a clinical
cardiac failure diagnosed by their own cardiologist before their
entry in the study. We contacted all these specialists in order to
verify this diagnostic of cardiac failure episode with clinical
congestive signs according to NYHA classification and to obtain
additional information. Table 1 presents the general characteristics
of the 447 pts and of their chemotherapy treatment.
Cardiac failure
The 24 pts who experienced cardiac failure were younger at the
time of the first adriamycin treatment than the 218 patients who
were not examined and the 205 asymptomatic patients who were
examined (Table 1). On the whole, patients who experienced
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(P¼0.01) and a higher radiation dose to the heart (P¼0.005) than
patients who had not.
As shown in Figure 1, the risk of cardiac failure increased
regularly with time since the first adriamycin treatment and attained
19% (95% Cl: 9–29%) 25 years later, for patients who had received
morethan250mgm
 2. Both adriamycin treatment and the average
dose of radiation to the heart played a significant independent role
in the risk of cardiac failure (Table 2). We evidenced a near
significant reduction in the risk for the 8 years or older age category
at the time of the first adriamycin treatment (Table 2), but we were
not able to evidence a threshold for a younger age. A detailed
analysis of the dose–response relationship was not possible because
of the small number of events. Compared to patients who had
received 250mgm
 2 or less, those who had received 250–
400mgm
 2 experienced a relative risk of cardiac failure of 1.93
(95% Cl: 0.49–5.8), and those who had received 400mgm
 2 or
more, a relative risk of 4.92 (95% Cl: 1.28–18.9). There was a trend
(P¼0.1) towards an interaction for a greater increase in the risk of
cardiac failure per amount of the adriamycin cumulative dose
among boys (RR for 100mgm
 2¼2.88, 95% Cl: 1.44–5.73) than
among girls (RR for 100mgm
 2¼1.70, 95% Cl: 0.78–3.69).
We were not able to evidence an excess risk for patients who had
received less than 5Gy of average radiation dose to the heart
(RR¼0.45, 95% Cl: 0.12–1.68), as compared to patients who had
not received radiotherapy. In contrast, those who had received an
average dose of between 5 and 20Gy had a relative risk of cardiac
failure of 2.52 (95% Cl: 0.96–6.60), and those who had received
20Gy or more, a relative risk of 5.65 (95% Cl: 1.45–22.0). In
Table 1 Study population
Examined or known cardiac failure
(n¼229)
Whole
population
(n¼447)
Not examined
and not known
cardiac failure
(n¼218)
Cardiac failure
(n¼24)
Asymptomatic
patients examined
(n¼205) P-value
a
Date of first adriamycin dose 1978 (1968–1982) 1978 (1972–1983) 1978 (1973–1985) 1978 (1968–1984) NS
Sex (M/F) 278/169 145/73 14/10 119/86 0.1
First cancer type
Unknown 3 1 0 2
Lymphoma 138 67 3 68
Neuroblastoma 64 25 6 33
Nephroblastoma 56 21 8 27 NS
Soft-tissue sarcoma 91 54 1 36
Osteosarcoma 15 5 1 9
Ewing sarcoma and PNET 33 19 2 12
Hepatoblastoma 8 4 0 4
UCNT and other carcinoma 7 2 1 4
Others 32 20 2 10
First cancer site
Unknown 2 1 0 1
Brain and spinal axis 5 2 1 2
Skull, face and orbit 51 28 0 23
Cervical 51 20 1 30
Thorax and mediastinum 49 20 5 24
Retroperitoneum 126 56 11 59
Abdominal cavity 45 22 0 23
Pelvis 52 32 3 17
Rachis 17 12 1 4
Limbs 49 25 2 22
Age at first anthracycline dose (min–max) 6.2 (0–21) 6.9 (0–16) 4.8 (1–13) 5.7 (0–21) 0.005
Total anthracycline dose: mean (min–max) (mgm
 2) 344 (40–600) 347 (60–600) 412 (180–600) 333 (40–600) 0.05
Radiotherapy: n (%) 245 (55%) 125 (57%) 14 (58%) 106 (52%) 0.3
Radiation dose to the heart: mean (min–max) (Gy) 6.7 (0–91) 5.2 (0–35) 13.4 (0–46) 7.7 (0–91) 0.3
Maximal radiation dose at a point in the heart: mean
(min–max) (Gy)
31.3 (0–125) 32.5 (0–102) 37.3 (0–745) 31.5 (0–125) 0.5
aComparison between the 205 pts not examined and the others.
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Figure 1 Risk of cardiac failure and time since anthracycline exposure.
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lTable 2 Prognostic factors for cardiac failure and cardiac disorder in 229 patients
Cardiac failure (n¼24) Cardiac disorder (n¼89)
a
Parameters Relative risk (95% CI) P-value Relative risk (95% CI) P-value
Gender
Male 1
b 1
b
Female 1.03 (0.45–2.37) NS 1.41 (0.8–2.6) NS
Age at first treatment
X8 years 1
b 1
b
0–7yrs 2.63 (0.87–7.96) 0.08 3.21 (1.63–6.34) o0.001
Cumulative anthracycline dose (RR at 100mgm
 2) 1.99 (1.30–3.01) o0.005 1.60 (1.22–2.09) o0.001
Average radiation dose (RR at Gy to the heart) 1.12 (0.95–1.29) o0.01 1.25 (0.99–1.50) o0.001
aAt least one of the following criteria: cardiac failure, FSo25, ESo50, or ESWS4100.
bReference category.
Table 3 Cardiac parameters in the 205 asymptomatic patients examined according to sex
Whole cohort
Sex
Cardiac parameters (205) Male (119) Female (86) P-value
FS
Mean (s.d.) 33 (5.7) 32 (5.7) 33 (5.8) 0.08
Median (min–max) 32 (13–47) 32 (14–47) 33 (13–46)
o20 4 2 2
[20–25[ 9 8 1
[25+ 192 108 82
EF
Mean (s.d.) 60 (8) 59 (8) 61 (8) 0.04
Median (min–max) 61 (29–78) 59 (29–78) 62 (29–78)
o40 5 2 3
[40–50 [ 12 9 3
[50+ 188 108 80
ESWS
Mean (s.d.) 93 (18) 90 (16) 96 (19) 0.06
Median (min–max) 91 (56–178) 91 (56–147) 94 (66–178)
o90 95 59 36
[90-100 [ 49 29 20
[100–125] 49 27 22
4125 12 4 8
ESWS/VTS ratio
Mean (s.d.) 2.3 (0.91) 2.0 (0.68) 2.7 (1.0)
Median (min–max) 2.2 (0.66–9.5) 1.9 (0.66–4.5) 2.6 (1.1–9.5) o0.001
o1.5 28 25 3
[1.5–1.75 [ 32 27 5
[1.75–2 [ 17 10 7
42 128 57 71
Cardiac MIBG: CM4 (199 pts studied)
Mean (s.d.) 1.9 (0.25) 1.9 (0.25) 1.9 (0.26) NS
Median (min–max) 1.9 (1.2–2.6) 1.9 (1.2–2.6) 1.9 (1.2–2.6)
o1.7 33 19 14
[1.7–2 [ 97 54 43
[2+ 69 43 26
BNP (154 pts studied)
Mean (s.d.) 17 (12) 17 (12) 18 (13) NS
Median (min–max) 19 (0–77) 17 (0–42) 20 (0.2–77)
o17 73 47 26
[17–25 [ 35 15 20
[25 30 [ 24 14 10
[30+ 22 15 7
Wave E/Wave A (202 pts studied)
Mean (s.d.) 1.9 (0.64) 1.8 (0.63) 1.9 (0.64) 0.1
Median (min–max) 1.7 (0.71–3.7) 1.7 (0.79–3.7) 1.8 (0.71–3.7)
o15 4 1
[1–1.5[ 57 37 20
[1.5+ 140 75 65
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the risk per average radiation dose to the heart seemed higher
(P¼0.08) among girls (RR at 1Gy¼1.18, 95% Cl: 0.91–1.44) than
among boys (RR at 1Gy¼1.09, 95% Cl: 0.93–1.25). Nevertheless,
such an interaction was not found when considering the maximal
dose received at any site of the heart.
We were able to evidence neither synergy between the effects of
adriamycin therapy and the radiation dose (P¼0.8) nor an
interaction. Nevertheless, the power of such a test was very low.
Among the 34 pts who had received 250mgm
 2 or more of
adriamycin and 5Gy or more to the heart, the 25-year risk of
cardiac failure (n¼8) was estimated to be 34% (95% Cl: 5–64%).
Of the 24 pts who experienced a cardiac failure, 11 received more
than 5Gy to the heart or more, 21 received more than 250mgm
 2
of adriamycin, and eight pts received both 5Gy or more to the
heart and more than 250mgm
 2 of adriamycin. Of these 24 pts,
two died before transplantation and three after.
Asymptomatic cardiac abnormalities
Among the 205 asymptomatic patients examined, four had severe
(FSo20%), and nine had marked (20pFSo25%) systolic
dysfunction, requiring treatment and a strict cardiac follow-up
(Table 3). This pattern was strongly linked to the cumulative
adriamycin dose (Po0.0001), after adjustment on sex, the type of
first cancer, radiation dose to the heart, age at first adriamycin
treatment and the interval since treatment (Table 4). Similarly, the
ejection fraction was significantly depressed in 17 pts, including
the 13 who had severe (n¼4) or marked (n¼9) systolic
dysfunction according to the FS criteria (P-value o0.01) for the
adjusted relationship with adriamycin therapy.
In terms of afterload, a total of 61 pts had an ESWS value
exceeding 100gcm
 2, of whom 52 did not present a severe or
marked systolic dysfunction, reflecting an abnormal load condition
likely to give rise to systolic function failure due to the thickness of
the ventricular wall. Furthermore, the ESWS/end-systolic volume
(ESV) ratio, which reflects ventricular contractility, was lower than
1.75 in 59 patients. The ESWS/ESV to left ventricular mass
(corrected by the body surface area) ratio, appears nonsignificantly
different in boys when compared to girls (Figure 2).
A total of 65 pts were found to have asymptomatic cardiac
disease (FSo25, ESo50, ESWS4100).
Cardiac I
131 MIBG uptake decreased with higher adriamycin
doses, but this was not related to the pathological status, defined as
a ratio below 1.7 (Table 4). In all, 15% of the patients with
asymptomatic cardiac abnormalities had a CM4 level below 1.7, as
compared to 19% of the others (P¼0.5).
Adriamycin treatment was not found to significantly modify the
serum BNP level (Table 4), and the 65 pts with asymptomatic
cardiac abnormalities had a serum BNP level similar to that of the
other patients (P¼0.8).
Adriamycin chemotherapy was not found to significantly
modify the E wave/A wave ratio (Table 4). In all, 34% of patients
with asymptomatic cardiac abnormalities had an E/A ratio below
1.5, as compared to 29% of the others (P¼0.5).
All cardiac diseases
A total of 89 patients were identified as having cardiac disease, that
is, a severe pathological cardiac status (FSo25%, EFo50%, or
ESWS4100gcm
 2) or cardiac failure.
The risk of cardiac disease decreased with an older age at the
time of cancer treatment, and increased with the total adriamycin
dose (Table 5) and with the average dose of radiation delivered to
the heart (Table 6).
Adriamycin cumulative dose There was no apparent threshold
for the relationship between the adriamycin dose and the risk of
cardiac disease (Tables 2 and 5). The dose–response relation was
found to be very similar in boys and girls (P-value for an
interaction with the sex of the patients: P¼0.9). Similarly, this
relation did not vary according to the age at treatment of the first
cancer either with the interval between treatment of the first cancer
and the time when cardiac parameters were measured or with
cardiac failure.
Radiation therapy dose exposure The risk of cardiac disease was
found to be 4.40-fold (95% Cl: 1.0–17. 5) higher for patients who
had received more than 20Gy to the heart than among those who
had not received radiotherapy (Table 6). In a manner similar to that
found for cardiac failure, we evidenced an interaction between sex
and the radiation dose: the excess risk per radiation dose unit was
found to be about three-fold higher among girls than boys
(P¼0.05). Greater sensitivity of girls to radiation explained almost
all the excess risk observed among girls. When the gender difference
in the radiation dose–response relationship was taken into account,
the residual excess risk for girls was found to be only 5%.
No significant interaction was found between the cumulative
adriamycin dose and that of radiation to the heart (Table 7). The
relative risk for a patient who had received both adriamycin
therapy and radiation was found to be not significantly different
from the product of the risks for each of these risk factors (P-value
for interaction¼0.9).
DISCUSSION
The aim of the present study was to determine the long-term risk
of cardiac disease after adriamycin therapy for a cancer in
childhood and the influence of other drugs and radiotherapy on
this risk. Our study failed to show a threshold for adriamycin-
induced cardiac toxicity, which clearly may occur after less than
250mgm
 2. We also failed to show any increased risk associated
with drugs considered noxious for cardiac or pulmonary function,
such as cyclophosphamide, ifosfamide, and bleomycin. We
evidenced a dose–response relationship for the radiation dose to
the heart, which was stronger among girls than among boys.
According to our results, higher sensitivity to radiation therapy
could account for the higher risk observed among girls in some
studies. Another important result was the very high risk of long-
term cardiac toxicity associated with high-dose adriamycin
therapy combined with radiation to the heart.
Among the 447 pts initially targeted in our roster, 218 patients
(49%) were not included. This could be the over-riding potential
source of bias in our study. These patients were more frequently
male and older than those who were known to have developed
cardiac failure or who were investigated. They had also received a
slightly higher dose of adriamycin and a lower dose of radiation to
the heart, but these differences disappeared after adjustment on
age. Seven of these patients died from an unknown cause (n¼1) or
causes nonlinked to cardiac disease. This selection strongly limits
our ability to assess the absolute value of the incidence of cardiac
failures and cardiac abnormality. On the contrary, it should have
little influence on our estimation of the relative risk of pathologies
associated with treatment by adriamycin and radiotherapy. Indeed,
when formulating the hypothesis, where none of the 218
nonincluded patients experienced such pathologies and analyses
on was performed the whole cohort of 447 patients, relative risk
estimations were extremely similar to those obtained on the 229
included patients.
The major findings of well-conducted studies were listed by
Kremer et al (2002). Unlike the results reported by Lipshultz et al
(1991, 1995) and Green et al (2001), we did not identify the female
sex as a significant independent risk factor for abnormal cardiac
function or cardiac failure, nor as a modifying factor of the dose–
response relationship between the adriamycin dose and the risk of
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(n¼89) and the range of doses were considerable in our study, our
results are not incompatible with the likelihood that female
patients may be more vulnerable to adriamycin treatment.
Nevertheless, about 80% of the nonsignificant excess risk we
observed among girls was explained by a higher risk for a given
dose of radiation to the heart (P¼0.02) and not by a higher
sensitivity to adriamycin therapy (P¼0.8).
In agreement with some studies (Lipshultz et al, 1991), but not
with others (Silber et al, 1993; Kremer et al, 2002), a younger age at
treatment was found to be a risk factor for both cardiac failure and
abnormalities. The age distribution in our series is wider than in
the first publication by Lipshultz et al (1991). In our opinion, this
age factor may not have been investigated adequately in that study
because the age range is far narrower and lower in acute leukaemia
than in solid tumours in children. However, the occurrence of
cardiac abnormalities probably increases with a younger age at
adriamycin treatment and with an older age at cardiac evaluation,
which are inversely correlated. In some studies, these two
parameters are very closely associated and therefore cannot be
investigated adequately.
In our series, we included all types of solid tumours, whereas
other studies included only lymphoblastic leukaemias (Sallan and
Clavell, 1984; Lipshultz et al, 1991; Sorensen et al, 1997; Nysom
Table 4 Cardiac parameters in the 205 asymptomatic patients examined according to cumulative anthracycline dose (mgm
 2)
Cumulative anthracycline dose (mgm
 2)
Crude Adjusteda
Cardiac parameters p150 151–250 251–400 4400 Relationship: P-value Relationships: P-value
FS
Mean (s.e.m.) 35 (0.9) 34 (0.8) 33 (0.6) 30 (0.9)
Median (min–max) 36 (27–42) 33 (24–42) 32 (20–47) 30 (13–43)
o2 0 0004
[20–25 [ 0 1 6 2 o0.0001 o0.0001
[25+ 20 30 87 55
EF
Mean (s.e.m.) 64 (1.1) 62 (1.0) 61 (0.8) 57 (1.3)
Median (min–max) 66 (53–73) 62 (47–73) 61 (41–78) 57 (29–74)
o4 0 0005
[40–50 [ 0 2 6 4 o0.01 o0.01
[50+ 20 29 86 53
ESWS
Mean (s.e.m.) 87 (2.7) 90 (2.1) 92 (1.7) 97 (2.9)
Median (min–max) 85 (70–119) 92 (66–110) 91 (56–135) 94 (62–178)
o90 13 15 45 22
[ 90–100 [ 4 9 16 20 o0.01 o0.01
[100–125] 2 7 29 11
4125 0 0 3 9
ESWS/VTS ratio
Mean (s.e.m.) 2.7 (0.17) 2.3 (0.13) 2.3 (0.08) 2.2 (0.15)
Median (min–max) 2.6 (1.2–4.0) 2.2 (1.4–3.9) 2.2 (1.2–4.8) 1.9 (0.7–9.5)
o1.5 1 4 11 12
[1.5–1.75 [ 0 6 13 13
[1.75–2 [ 1 1 6 9 o0.001 0.03
o2 1 72 06 32 8
Cardiac MIBG: CM4 (199 pts studied)
Mean (s.e.m.) 2.0 (0.05) 1.9 (0.06) 1.9 (0.03) 1.9 (0.03)
Median (min–max) 2.1 (1.6–2.3) 1.8 (1.3–2.6) 1.9 (1.2–2.5) 1.9 (1.2–2.6)
o1.7 3 7 11 11
[1.7–2 [ 6 13 48 31 NS 0.01
[2+ 10 10 29 20
BNP (154 pts studied)
Mean (s.e.m.) 20 (3.1) 17 (2.2) 17 (1.4) 20 (3.1)
Median (min–max) 24 (1.7–38) 20 (0.3–36) 18 (0–39) 17 (0.2–78)
o17 6 11 33 23
[17–25[ 3 9 13 10
[25 30 [ 4 3 12 5 NS NS
[30+ 3 2 10 7
Wave E/Wave A (202 pts studied)
Mean (s.e.m.) 1.9 (0.1) 1.8 (0.1) 1.8 (0.07) 1.9 (0.09)
Median (min–max) 1.8 (10–3.0) 1.7 (0.9–3.3) 1.7 (0.8–3.7) 1.8 (0.7–3.7)
o1 0113
[ 1–1.5[ 4 10 28 15 NS NS
[1.5+ 16 20 60 44
aAdjusted on sex, type of first cancer, radiation dose to the heart, age at administration, and interval between treatment of first cancer and cardiac examination.
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let al, 1998), osteosarcoma (Lipshultz et al, 1995), or Wilms’
tumour (Sorensen et al, 1995; Green et al, 2001). When the two
former types were excluded (n¼71), our results remained
unmodified.
We demonstrated the role of the radiation dose to the heart.
This result was suggested in some studies (Steinherz et al, 1991,
1993, 1995), where radiotherapy (RT) vs no RT was studied. A total
of 120 patients investigated had received radiotherapy, at some site
in the body. During radiotherapy, the radiation dose to the heart is
due to primary and scattered radiation if the heart is inside the
beam field, and to scattered radiation only, if the heart is outside
the target volume. Even if the heart is less than a tenth of a cm
from the beams, the scattered radiation received outside the beam
field is not, however, negligible. We estimated the radiation dose
received at 6 points in the heart. An average dose of 5Gy or more
had been delivered to the heart in 52 pts: an increased risk of
cardiac disease was demonstrated above 5Gy in this study. The
other 68 pts who had received less than 5Gy were not at increased
risk. The role of radiotherapy is well-known (Pai and Nahata, 2000;
Green et al, 2001; Kremer et al, 2002), but no dose–response
relationship has been demonstrated.
For adriamycin doses higher than 150mgm
 2, we failed to
evidence a threshold in the dose–response relationship between
adriamycin therapy and both cardiac failure and all cardiac
abnormalities in general. This is in agreement with the report of a
study limited to the shortening fraction (Bu’Lock et al, 1995).
Another study was not able to investigate the dose–response
relationship for doses lower than 250mgm
 2 with sufficient
statistical power because most patients had received more than
this dose (Lipshultz et al, 1991, 1995). However, in Green’s case–
control study (Green et al, 2001), the odds-ratio (OR) for a dose
ranging from 200 to 300mgm
 2 was 1.1 (95% Cl: 0.3–51), which is
lower than our OR of 2.0 for doses from 150 to 250mgm
 2 and 4.0
for doses from 250 to 400mgm
 2. A difference in the duration of
follow-up cannot explain this discrepancy. Owing to the standar-
disation of the protocols used before 1982, we were unable to
investigate the role of the cumulative dose and that of the dose per
injection separately, as of great interest in several studies (Von
Hoff et al, 1979; Sallan and Clavell, 1984; Lipshultz et al, 1995).
Practically, all our patients had received a 60mgm
 2 dose as a
bolus injection every 3 weeks.
Like other authors, we found that the risk of cardiac failure
increased regularly with time since adriamycin therapy (Figure 1),
with no suggestion of a plateau.
Since we found no evidence suggesting an interaction between
adriamycin and the effect of radiation on the risk of cardiac failure,
we estimated the risk for patients who had received both
treatments, not significantly different from the product of the
risks for each treatment. Consequently, patients who had received
high doses of each treatment had to be considered particularly at
risk of cardiac failure.
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Figure 2 Pressure to volume ratio, according to corrected left
ventricular mass in female and male.
Table 5 Dose–response relationship between the cumulative anthracy-
cline dose and the occurrence of a cardiac abnormality in the 229 patients
with known cardiac status
Cardiac abnormality
a
Parameters % (nb/N)
Relative risk
b
and 95% CI P-value
Cumulative anthracycline
dose (mgm
 2)
0–150 10% (2/20) 1
c
4150–250 29% (10/34) 2.0 (0.44–9.5)
4250–400 43% (43/99) 4.0 (0.95–17) o0.001
4400 45% (34/76) 3.3 (0.78–14)
aAt least one of the following criteria: cardiac failure, FSo25, ESo50, or
ESWS4100.
bAdjusted for age at treatment of first cancer, sex, and average
radiation dose received at 6 points in the heart, and stratified on the site of the
cancer.
cReference category.
Table 6 Dose–response relationship between the average radiation
dose to the heart and the occurrence of a cardiac abnormality in 229
patients with known cardiac status
Cardiac abnormality
a
Parameters % (nb/N)
Relative risk
b
and 95% CI P-value
Average radiation dose
0 (no radiotherapy) 29% (32/109) 1
c
40–5Gy 37% (25/68) 1.63 (0.82–3.26)
45–20Gy 63% (26/41) 6.48 (2.76–15.20) o0.001
420Gy 55% (6/11) 4.40 (1.11–17.48)
aAt least one of the following criteria: cardiac failure, FSo25, ESo50, or
ESWS4100.
bAdjusted for age at treatment of 1st cancer, sex, and cumulative
anthracyline dose, and stratified on the site of the cancer.
cReference category.
Table 7 Frequency of cardiac abnormality in 229 pts according to the
cumulative dose of adriamycin and to the average radiation dose received
to the heart
Parameters
Cardiac abnormality
a
Cumulative dose of
adriamycin and average
radiation dose to the heart % (nb/N)
Relative risk
b
and 95% CI P-value
o250mg of adriamycin
o5Gy to the heart 11% (4/32) 1
c
X5Gy to the heart 44% (8/18) 4.9 (1.3–18.0) 0.02
X250mg of adriamycin
o5Gy to the heart 38% (53/141) 5.1 (1.8–14.5) 0.003
X5Gy to the heart 71% (24/34) 6.6 (2.1–20.6) 0.001
aAt least one of the following criteria: cardiac failure, FSo25, ESo50, or
ESWS4100.
bAdjusted for age at treatment of first cancer, and sex, and stratified
on the site of the cancer.
cReference category.
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An increased incidence of cardiac failure and severe cardiac
abnormalities with long-term follow-up seen in our study is in
accordance with previously published results. The major added
cause for concern is the continuous increase in the occurrence of
cardiac failure with time, with no sign of a plateau from exposure
up to 15 and 25 years of follow-up. In our series, after an average
follow-up of 18 years, 39% of the children had a severe cardiac
dysfunction or major ventricular overload conditions. As the usual
age for the occurrence of cardiac failure in the general population
starts from 50 years onwards, this increased incidence of cardiac
disorders in cancer survivors who were exposed to adriamycin
during childhood could be compounded as they approach the age
of 50 years. The higher risk of cardiac failure and abnormalities for
the female gender observed in other studies, was found in our
study to be essentially due to the higher sensitivity of girls to
radiation therapy rather than to a higher sensitivity to the
cumulative adriamycin dose in itself.
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